7-150951552-G-A
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_000238.4(KCNH2):c.1841C>T(p.Ala614Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,872 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000238.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
KCNH2 | NM_000238.4 | c.1841C>T | p.Ala614Val | missense_variant | 7/15 | ENST00000262186.10 | NP_000229.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
KCNH2 | ENST00000262186.10 | c.1841C>T | p.Ala614Val | missense_variant | 7/15 | 1 | NM_000238.4 | ENSP00000262186 | P1 |
Frequencies
GnomAD3 genomes Cov.: 34
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461872Hom.: 0 Cov.: 34 AF XY: 0.00000138 AC XY: 1AN XY: 727240
GnomAD4 genome Cov.: 34
ClinVar
Submissions by phenotype
Long QT syndrome 2 Pathogenic:4
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 10, 2011 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Oct 19, 2020 | Based on the classification scheme VCGS_Germline_v1.1.1, this variant is classified as Pathogenic. Following criteria are met: 0103 - Both loss- and gain-of-function and dominant negative are known mechanisms of disease for this gene. Loss of function and dominant negative are disease mechanisms for long QT syndrome 2 (MIM#613688), whereas gain of function is a disease mechanism for short QT syndrome 1 (MIM#609620). (N) 0107 - This gene is known to be associated with autosomal dominant disease. (N) 0112 - Variants in this gene are known to have reduced penetrance (GeneReview). (N) 0200 - Variant is predicted to result in a missense amino acid change from alanine to valine (exon 7). (N) 0251 - Variant is heterozygous. (N) 0301 - Variant is absent from gnomAD. (P) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (P) 0600 - Variant is located in the pore forming region (PMID: 9721698). (N) 0801 - Strong previous evidence of pathogenicity in unrelated individuals. The variant has been previously reported in multiple patients with LQTS (ClinVar). (P) 1002 - Moderate functional evidence supporting abnormal protein function. In addition, functional studies show that this variant causes LQTS through dominant negative mechanism (PMID: 9721698, 21240260). (P) 1208 - Inheritance information for this variant is not currently available. (N) Legend: (P) - Pathogenic, (N) - Neutral, (B) - Benign - |
Pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Sep 10, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | KardioGenetik, Herz- und Diabeteszentrum NRW | Jun 17, 2024 | PP3moderate, PM2supporting, PP2, PM1, PS4moderate, PS3 - |
Long QT syndrome Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 21, 2022 | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects KCNH2 function (PMID: 16432067, 19057127, 23303164, 25417810). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 29777). This missense change has been observed in individuals with long QT syndrome (PMID: 9024139, 9544837, 15090700, 18441445, 18808722, 19057127, 19996378, 22949429). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 614 of the KCNH2 protein (p.Ala614Val). - |
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute | Aug 30, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 07, 2018 | Variant summary: KCNH2 c.1841C>T (p.Ala614Val) results in a non-conservative amino acid change located in the Ion transport domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 250692 control chromosomes. c.1841C>T has been reported in the literature in numerous individuals affected with Long QT Syndrome. These data indicate that the variant is very likely to be associated with disease. Several publications report experimental evidence evaluating an impact on protein function, such as electrophysiological findings (Itzhaki_2011) and intracellular trafficking (Anderson_2006), both of which were impaired in the presence of the variant. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 13, 2022 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies demonstrate a damaging effect as this variant exerts a dominant negative effect (Anderson et al., 2006; Sakaguchi et al., 2008; Itzhaki et al., 2011; Jou et al., 2013); Reported in ClinVar as a pathogenic variant (ClinVar Variant ID# 29777); This variant is associated with the following publications: (PMID: 19057127, 22949429, 27555138, 19841300, 19716085, 18441445, 25417810, 18752142, 21703926, 21367833, 19070294, 31557540, 19843919, 23303164, 16432067, 25467552, 21240260, 9544837, 9927399, 9024139, 28316956, 28718902, 23864605, 15840476, 18808722, 15090700, 19996378, 11854117, 10560244, 21295269, 21185501, 10973849, 9693036, 9721698) - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 10, 2021 | The p.A614V pathogenic mutation (also known as c.1841C>T), located in coding exon 7 of the KCNH2 gene, results from a C to T substitution at nucleotide position 1841. The alanine at codon 614 is replaced by valine, an amino acid with similar properties, and is located in the H5 intramembrane pore-forming region between transmembrane helices S5 and S6. This alteration has been identified in many unrelated patients with classic long QT syndrome (LQTS), reported to co-segregate with disease, and identified as a de novo mutation in LQTS probands without familial disease (Tanaka T et al. Circulation, 1997 Feb;95:565-7; Satler CA et al. Hum. Genet., 1998 Mar;102:265-72; Splawski I et al. Genomics, 1998 Jul;51:86-97; Priori SG et al. Circulation, 1999 Feb;99:529-33; Tenenbaum M et al. Isr. Med. Assoc. J., 2008 Nov;10:809-11; Kumakura M et al. J Clin Anesth, 2016 Sep;33:81-5). Numerous functional studies have demonstrated this alteration results in prolonged action-potential duration due to the loss of function of the IKr channel by deficient intracellular protein transport to the cell surface membrane (Nakajima T et al. Circ. Res., 1998 Aug;83:415-22; Sakaguchi T et al. J. Pharmacol. Sci., 2008 Dec;108:462-71; Itzhaki I et al. Nature, 2011 Mar;471:225-9; Jou CJ et al. Circ. Res., 2013 Mar;112:826-30). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Congenital long QT syndrome Other:1
not provided, no classification provided | literature only | Cardiovascular Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust | - | This variant has been reported as associated with Long QT syndrome in the following publications (PMID:9024139;PMID:9544837;PMID:9693036;PMID:9927399;PMID:10560244;PMID:11854117;PMID:15840476;PMID:16432067;PMID:18441445;PMID:18752142;PMID:19057127;PMID:19716085;PMID:19841300;PMID:19843919;PMID:10187793). This is a literature report, and does not necessarily reflect the clinical interpretation of the Imperial College / Royal Brompton Cardiovascular Genetics laboratory. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at